We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

COVID-19 was associated with more severe disease outcomes than influenza or RSV during the 2022 to 2023 season.

While the number of people seeking medical help with acute respiratory infection, including influenza-like illness keeps ...

Virbac is expanding its U.S. cattle range of products with four vaccines — Bovigen Platinum 5, Bovigen Platinum 5 L5, Bovigen ...

Respiratory Syncytial Virus, or RSV, has dominated headlines with an influx of cases across the country and here in Western ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.

“RSV isn’t reportable, but surveillance shows an uptick in cases. Fortunately, we now have vaccines for older adults and antibody treatments for babies,” Meyerson said. Meyerson ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.